Article

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

2024-01-03

Abstract excerpt

We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five years. Patients were included according to the French marketing authorization in 2016 (i.e. patients with relapsed or refractoryCLL or to previously untreated CLL patients with deletion 17p and/or TP53 mutations...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f34707b3-8734-5c48-8881-2ecff962feed
DOI: 10.21203/rs.3.rs-3809070/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE studyDOI 10.21203/rs.3.rs-3809070/v1Read

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.Semantic proximity Read

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read

Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.Semantic proximity Read

Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.Semantic proximity Read

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upSemantic proximity Read

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohortSemantic proximity Read

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Semantic proximity Read

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.Semantic proximity Read

Update on therapy of chronic lymphocytic leukemia.Semantic proximity Read

[Chronic lymphocytic leukemia : treatment concepts in transition].Semantic proximity Read

Recent therapeutic advances in chronic lymphocytic leukemiaSemantic proximity Read

Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.Semantic proximity Read